Atrion Corporation (NASDAQ: ATRI) Stock Competitors & Peer Comparison
See ATRI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATRI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATRI | $459.92 | +0.06% | 809.4M | 64.50 | $7.13 | +1.91% |
| ISRG | $410.76 | +1.38% | 146.5B | 43.12 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.17% |
| BDX | $181.68 | -1.16% | 50.7B | 14.15 | $13.00 | +2.17% |
| RMD | $222.40 | +0.18% | 32.2B | 20.64 | $10.77 | +1.11% |
| MDLN | $34.95 | +0.73% | 29.7B | 25.70 | $1.36 | N/A |
| WST | $375.21 | +1.29% | 26.4B | 44.20 | $8.50 | +0.23% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $89.28 | -0.25% | 15.5B | 12.61 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.17% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
ATRI vs ISRG Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ISRG has a market cap of 146.5B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ISRG trades at $410.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ISRG's P/E ratio is 43.12. In terms of profitability, ATRI's ROE is +0.08%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, ATRI is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
ATRI vs BDXA Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BDXA's P/E ratio is 45.70. In terms of profitability, ATRI's ROE is +0.08%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, ATRI is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
ATRI vs BDX Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BDX has a market cap of 50.7B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BDX trades at $181.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BDX's P/E ratio is 14.15. In terms of profitability, ATRI's ROE is +0.08%, compared to BDX's ROE of +0.04%. Regarding short-term risk, ATRI is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
ATRI vs RMD Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RMD has a market cap of 32.2B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RMD trades at $222.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RMD's P/E ratio is 20.64. In terms of profitability, ATRI's ROE is +0.08%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ATRI is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
ATRI vs MDLN Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MDLN has a market cap of 29.7B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MDLN trades at $34.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MDLN's P/E ratio is 25.70. In terms of profitability, ATRI's ROE is +0.08%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, ATRI is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
ATRI vs WST Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, WST has a market cap of 26.4B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while WST trades at $375.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas WST's P/E ratio is 44.20. In terms of profitability, ATRI's ROE is +0.08%, compared to WST's ROE of +0.19%. Regarding short-term risk, ATRI is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
ATRI vs HOLX Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HOLX's P/E ratio is 31.54. In terms of profitability, ATRI's ROE is +0.08%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, ATRI is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
ATRI vs SOLV Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, SOLV has a market cap of 15.5B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while SOLV trades at $89.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas SOLV's P/E ratio is 12.61. In terms of profitability, ATRI's ROE is +0.08%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, ATRI is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
ATRI vs BDXB Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BDXB's P/E ratio is 7.60. In terms of profitability, ATRI's ROE is +0.08%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, ATRI is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
ATRI vs BAX Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BAX has a market cap of 12.1B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BAX trades at $23.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BAX's P/E ratio is 11.30. In terms of profitability, ATRI's ROE is +0.08%, compared to BAX's ROE of -0.17%. Regarding short-term risk, ATRI is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
ATRI vs COO Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, COO has a market cap of 11B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while COO trades at $56.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas COO's P/E ratio is 12.41. In terms of profitability, ATRI's ROE is +0.08%, compared to COO's ROE of +0.07%. Regarding short-term risk, ATRI is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
ATRI vs RGEN Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RGEN has a market cap of 11B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RGEN trades at $193.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RGEN's P/E ratio is 107.83. In terms of profitability, ATRI's ROE is +0.08%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, ATRI is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
ATRI vs AVTR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AVTR has a market cap of 10.3B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AVTR trades at $15.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AVTR's P/E ratio is 17.99. In terms of profitability, ATRI's ROE is +0.08%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, ATRI is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
ATRI vs ATR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ATR has a market cap of 7.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ATR trades at $122.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ATR's P/E ratio is 21.75. In terms of profitability, ATRI's ROE is +0.08%, compared to ATR's ROE of +0.14%. Regarding short-term risk, ATRI is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
ATRI vs BLCO Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BLCO trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BLCO's P/E ratio is 26.12. In terms of profitability, ATRI's ROE is +0.08%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, ATRI is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
ATRI vs STVN Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STVN trades at $21.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STVN's P/E ratio is 32.52. In terms of profitability, ATRI's ROE is +0.08%, compared to STVN's ROE of +0.09%. Regarding short-term risk, ATRI is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
ATRI vs TFX Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, TFX has a market cap of 5.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while TFX trades at $124.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas TFX's P/E ratio is 14.55. In terms of profitability, ATRI's ROE is +0.08%, compared to TFX's ROE of -0.32%. Regarding short-term risk, ATRI is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
ATRI vs MMSI Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MMSI trades at $86.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MMSI's P/E ratio is 22.25. In terms of profitability, ATRI's ROE is +0.08%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, ATRI is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
ATRI vs ICUI Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ICUI has a market cap of 4.1B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ICUI trades at $162.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ICUI's P/E ratio is 20.48. In terms of profitability, ATRI's ROE is +0.08%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, ATRI is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
ATRI vs NVST Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NVST has a market cap of 3.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NVST trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NVST's P/E ratio is 16.14. In terms of profitability, ATRI's ROE is +0.08%, compared to NVST's ROE of +0.03%. Regarding short-term risk, ATRI is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
ATRI vs PLSE Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, PLSE has a market cap of 3.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while PLSE trades at $50.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas PLSE's P/E ratio is -44.34. In terms of profitability, ATRI's ROE is +0.08%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, ATRI is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
ATRI vs ATRC Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ATRC has a market cap of 3B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ATRC trades at $57.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ATRC's P/E ratio is 1813.98. In terms of profitability, ATRI's ROE is +0.08%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, ATRI is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
ATRI vs BLFS Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BLFS trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BLFS's P/E ratio is 38.01. In terms of profitability, ATRI's ROE is +0.08%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, ATRI is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
ATRI vs LMAT Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while LMAT trades at $81.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas LMAT's P/E ratio is 30.27. In terms of profitability, ATRI's ROE is +0.08%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, ATRI is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check LMAT's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
ATRI vs XRAY Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while XRAY trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas XRAY's P/E ratio is 6.49. In terms of profitability, ATRI's ROE is +0.08%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, ATRI is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check XRAY's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
ATRI vs KMTS Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while KMTS trades at $28.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas KMTS's P/E ratio is -10.62. In terms of profitability, ATRI's ROE is +0.08%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, ATRI is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check KMTS's competition here
Azenta, Inc. (NASDAQ: AZTA)
ATRI vs AZTA Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AZTA trades at $34.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AZTA's P/E ratio is 81.55. In terms of profitability, ATRI's ROE is +0.08%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, ATRI is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check AZTA's competition here
STAAR Surgical Company (NASDAQ: STAA)
ATRI vs STAA Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STAA has a market cap of 1B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STAA trades at $22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STAA's P/E ratio is 36.61. In terms of profitability, ATRI's ROE is +0.08%, compared to STAA's ROE of +0.01%. Regarding short-term risk, ATRI is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STAA's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
ATRI vs ANGO Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ANGO has a market cap of 642.3M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ANGO trades at $15.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ANGO's P/E ratio is -39.85. In terms of profitability, ATRI's ROE is +0.08%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, ATRI is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
ATRI vs EMBC Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, EMBC has a market cap of 351.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while EMBC trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas EMBC's P/E ratio is 2.28. In terms of profitability, ATRI's ROE is +0.08%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ATRI is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
ATRI vs SMTI Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, SMTI has a market cap of 322.7M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while SMTI trades at $35.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas SMTI's P/E ratio is -585.00. In terms of profitability, ATRI's ROE is +0.08%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, ATRI is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
ATRI vs OSUR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, OSUR has a market cap of 272M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while OSUR trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas OSUR's P/E ratio is -5.72. In terms of profitability, ATRI's ROE is +0.08%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, ATRI is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check OSUR's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
ATRI vs NNNN Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NNNN has a market cap of 267.3M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NNNN trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NNNN's P/E ratio is 37.20. In terms of profitability, ATRI's ROE is +0.08%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, ATRI is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NNNN's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
ATRI vs UTMD Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, UTMD has a market cap of 237.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while UTMD trades at $74.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas UTMD's P/E ratio is 22.04. In terms of profitability, ATRI's ROE is +0.08%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, ATRI is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
ATRI vs PDEX Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, PDEX has a market cap of 228.7M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while PDEX trades at $69.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas PDEX's P/E ratio is 17.34. In terms of profitability, ATRI's ROE is +0.08%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, ATRI is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
ATRI vs KRMD Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, KRMD has a market cap of 140.6M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while KRMD trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas KRMD's P/E ratio is -76.50. In terms of profitability, ATRI's ROE is +0.08%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, ATRI is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
ATRI vs STXS Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STXS has a market cap of 122.9M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STXS trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STXS's P/E ratio is -7.38. In terms of profitability, ATRI's ROE is +0.08%, compared to STXS's ROE of -1.33%. Regarding short-term risk, ATRI is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
ATRI vs DXR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, DXR has a market cap of 66.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while DXR trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas DXR's P/E ratio is 9.22. In terms of profitability, ATRI's ROE is +0.08%, compared to DXR's ROE of +0.13%. Regarding short-term risk, ATRI is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
ATRI vs AKYA Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AKYA's P/E ratio is -1.34. In terms of profitability, ATRI's ROE is +0.08%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, ATRI is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
ATRI vs STSS Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STSS's P/E ratio is -0.02. In terms of profitability, ATRI's ROE is +0.08%, compared to STSS's ROE of -1.54%. Regarding short-term risk, ATRI is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
ATRI vs OMIC Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas OMIC's P/E ratio is -0.58. In terms of profitability, ATRI's ROE is +0.08%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, ATRI is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
ATRI vs IGAP Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IGAP's P/E ratio is -10.52. In terms of profitability, ATRI's ROE is +0.08%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, ATRI is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
ATRI vs POCI Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, POCI has a market cap of 49.5M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while POCI trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas POCI's P/E ratio is -7.18. In terms of profitability, ATRI's ROE is +0.08%, compared to POCI's ROE of -0.37%. Regarding short-term risk, ATRI is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check POCI's competition here
Nephros, Inc. (NASDAQ: NEPH)
ATRI vs NEPH Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NEPH has a market cap of 43.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NEPH trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NEPH's P/E ratio is 67.17. In terms of profitability, ATRI's ROE is +0.08%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, ATRI is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
ATRI vs MLSS Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MLSS has a market cap of 37.1M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MLSS's P/E ratio is -8.40. In terms of profitability, ATRI's ROE is +0.08%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, ATRI is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
ATRI vs HBIO Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HBIO trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HBIO's P/E ratio is -22.17. In terms of profitability, ATRI's ROE is +0.08%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, ATRI is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
ATRI vs SDC Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas SDC's P/E ratio is -0.03. In terms of profitability, ATRI's ROE is +0.08%, compared to SDC's ROE of -1.96%. Regarding short-term risk, ATRI is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
ATRI vs IVC Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IVC's P/E ratio is -0.79. In terms of profitability, ATRI's ROE is +0.08%, compared to IVC's ROE of -0.46%. Regarding short-term risk, ATRI is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
ATRI vs RVP Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RVP has a market cap of 20.7M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RVP's P/E ratio is -5.77. In terms of profitability, ATRI's ROE is +0.08%, compared to RVP's ROE of -0.05%. Regarding short-term risk, ATRI is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
ATRI vs BNGO Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BNGO has a market cap of 19.3M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BNGO trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BNGO's P/E ratio is -0.56. In terms of profitability, ATRI's ROE is +0.08%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, ATRI is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
ATRI vs ZJYL Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ZJYL has a market cap of 15.3M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ZJYL trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ZJYL's P/E ratio is 13.34. In terms of profitability, ATRI's ROE is +0.08%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, ATRI is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
ATRI vs RGNT Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RGNT has a market cap of 13.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RGNT trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RGNT's P/E ratio is -0.08. In terms of profitability, ATRI's ROE is +0.08%, compared to RGNT's ROE of N/A. Regarding short-term risk, ATRI is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
ATRI vs FEMY Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, FEMY has a market cap of 7.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while FEMY trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas FEMY's P/E ratio is -0.53. In terms of profitability, ATRI's ROE is +0.08%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, ATRI is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
ATRI vs LUCY Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, LUCY has a market cap of 6M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while LUCY trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas LUCY's P/E ratio is -0.74. In terms of profitability, ATRI's ROE is +0.08%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, ATRI is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check LUCY's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
ATRI vs CUPR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, CUPR has a market cap of 5.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while CUPR trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas CUPR's P/E ratio is -1.41. In terms of profitability, ATRI's ROE is +0.08%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, ATRI is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check CUPR's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
ATRI vs NSTG Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NSTG's P/E ratio is -0.03. In terms of profitability, ATRI's ROE is +0.08%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, ATRI is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
ATRI vs POAI Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas POAI's P/E ratio is -0.03. In terms of profitability, ATRI's ROE is +0.08%, compared to POAI's ROE of -21.19%. Regarding short-term risk, ATRI is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
ATRI vs MHUA Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MHUA's P/E ratio is 0.25. In terms of profitability, ATRI's ROE is +0.08%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, ATRI is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
ATRI vs GMVD Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas GMVD's P/E ratio is -0.01. In terms of profitability, ATRI's ROE is +0.08%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, ATRI is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
ATRI vs GMVDW Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas GMVDW's P/E ratio is N/A. In terms of profitability, ATRI's ROE is +0.08%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, ATRI is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
ATRI vs AVGR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AVGR's P/E ratio is -0.05. In terms of profitability, ATRI's ROE is +0.08%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, ATRI is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
ATRI vs NXGL Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NXGL trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NXGL's P/E ratio is -0.25. In terms of profitability, ATRI's ROE is +0.08%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, ATRI is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
ATRI vs NXGLW Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NXGLW has a market cap of 946K. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, ATRI's ROE is +0.08%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, ATRI is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
ATRI vs LUCYW Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas LUCYW's P/E ratio is N/A. In terms of profitability, ATRI's ROE is +0.08%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, ATRI is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
ATRI vs ATRS Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ATRS's P/E ratio is 14.95. In terms of profitability, ATRI's ROE is +0.08%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, ATRI is less volatile compared to ATRS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
ATRI vs ALOG Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ALOG's P/E ratio is 40.93. In terms of profitability, ATRI's ROE is +0.08%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, ATRI is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check ALOG's competition here
IntriCon Corporation (NASDAQ: IIN)
ATRI vs IIN Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IIN has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IIN's P/E ratio is 226.45. In terms of profitability, ATRI's ROE is +0.08%, compared to IIN's ROE of -0.00%. Regarding short-term risk, ATRI is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check IIN's competition here
Invuity, Inc. (NASDAQ: IVTY)
ATRI vs IVTY Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IVTY's P/E ratio is -3.80. In terms of profitability, ATRI's ROE is +0.08%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, ATRI is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check IVTY's competition here
Apria, Inc. (NASDAQ: APR)
ATRI vs APR Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, APR has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas APR's P/E ratio is 22.59. In terms of profitability, ATRI's ROE is +0.08%, compared to APR's ROE of +9.81%. Regarding short-term risk, ATRI is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
ATRI vs HRC Comparison October 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HRC has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HRC's P/E ratio is 41.92. In terms of profitability, ATRI's ROE is +0.08%, compared to HRC's ROE of +0.14%. Regarding short-term risk, ATRI is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check HRC's competition here